Drug intelligence / Profile preview

RGH-202

Development stage: Unknown
Lead developer: Gedeon Richter
Modality: Small Molecules
Administration: Oral

Overview

RGH-202 (also known as Compound-202) is an investigational small molecule drug being developed by Gedeon Richter for the treatment of autism spectrum disorder (ASD). It acts as a ligand targeting the GABAB receptor, aiming to modulate neurotransmitter levels in the brain to address the core symptoms of ASD. RGH-202 completed Phase I clinical testing in healthy volunteers in the United Kingdom under the trial codes HMR 23-006 and HMR 23-007, and has advanced into Phase II clinical development.

Other names: HMR 23-006HMR23-006HMR-23-006HMR 23-007HMR23-007HMR-23-007

Targets

GABA-B (Gamma-aminobutyric acid receptor type B)

Beyond the preview

Go deeper on RGH-202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RGH-202.

Explore the full profile